Summary: The presentation concerns Pharmexa's RAS peptide vaccines in patients
with resectable pancreatic cancer
Professor Trond Buanes from Ullevål University Hospital in Norway will on
Monday June 4, 2007 present a poster titled ”RAS peptide vaccination in
resected pancreatic cancer patients - persistence of anti tumour response and
long term survival” at ASCO's (American Society of Clinical Oncology) annual
cancer meeting.
The data concerns treatment of patients with resectable pancreatic cancer with
two peptide vaccines aimed at a specific cancer mutation known as RAS. Rights
to these vaccines belong to Pharmexa.
The 2007 ASCO conference will take place from June 1 to June 5 in Chicago,
Illinois. It is widely regarded as the most important cancer conference in the
world and attracted around 30,000 attendants last year.
Hørsholm, May 29, 2007
Jakob Schmidt
Chief Executive Officer
Additional information: Jakob Schmidt, Chief Executive Officer, telephone +45
4516 2525
Claude Mikkelsen, Head of Investor Relations, telephone +45 4516 2525 or +45
4060 2558
Note to editors: Pharmexa A/S is a leading company in the field of active
immunotherapy and vaccines for the treatment of cancer, serious chronic and
infectious diseases. Pharmexa's proprietary technology platforms are broadly
applicable, allowing the company to address critical targets in cancer, bone
degeneration and Alzheimer's disease, as well as serious infectious diseases
such as HIV, influenza, hepatitis and malaria. Its leading programs are GV1001,
a peptide vaccine that has entered phase III trials in pancreatic cancer and
phase II trials in liver cancer, and HIV and hepatitis vaccines in phase I/II.
Collaborative agreements include H. Lundbeck, Innogenetics, IDM Pharma,
ImmunoVaccine Technologies and Bavarian Nordic. With operations in Denmark,
Norway and USA, Pharmexa employs approximately 105 people and is listed on the
Copenhagen Stock Exchange under the trading symbol PHARMX.
